Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer

Table 2 Radiological response in group immune checkpoint inhibitor and group non-immune checkpoint inhibitor, n (%)

Variable	Group A (n = 53)	Group B (n = 29)	P value
CR	7 (13.2)	0 (0.0)	0.048
PR	30 (56.6)	9 (31.0)	0.037
SD	15 (28.3)	18 (62.1)	0.004
PD	1 (1.9)	2 (6.7)	0.549
ORR	37 (69.8)	9 (31.0)	0.001
DCR	52 (98.1)	27 (93.1)	0.284

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.